In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on PAVmed (PAVM – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $2.22.
According to TipRanks, Takkinen is an analyst with an average return of -4.5% and a 39.90% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as ClearPoint Neuro, Inotiv, and EDAP TMS.
Currently, the analyst consensus on PAVmed is a Strong Buy with an average price target of $15.00.
The company has a one-year high of $7.75 and a one-year low of $1.60. Currently, PAVmed has an average volume of 63.34K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PAVmed (PAVM) Company Description:
PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The company was founded on June 26, 2014 and is headquartered in New York, NY.
Read More on PAVM:
- PAVmed Inc Provides Informal Financial Performance Update
- PAVmed Provides Business Update and First Quarter 2024 Financial Results
- Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
- PAVM Earnings this Week: How Will it Perform?
- Lucid SOS esophageal cell collection device subject to Class II FDA recall
